The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C
Open accessAbstract
The aim of this retrospective cohort study was to assess the cumulative development incidence and predictive factors for malignancies after the termination of interferon (IFN) therapy in Japanese patients for hepatitis C virus (HCV). A total of 4,302 HCV-positive patients treated with IFN were enrolled. The mean observation period was 8.1 years. The primary outcome was the first onset of malignancies. Evaluation was performed using the Kaplan-Meier method and Cox proportional hazard analysis. A total of 606 patients developed malignancies: 393 developed hepatocellular carcinoma (HCC) and 213 developed malignancies other than HCC. The cumulative development rate of HCC was 4.3% at 5 years, 10.5% at 10 years, and 19.7% at 15 years. HCC occurred significantly ( P < 0.05) when the following characteristics were present: advanced histological staging, sustained virological response not achieved, male sex, advanced age of ≥50 years, total alcohol intake of ≥200 kg, and presence of type 2 diabetes (T2DM). T2DM caused a 1.73-fold enhancement in HCC development. In patients with T2DM, HCC decreased when patients had a mean hemoglobin A1c (HbA1c) level of <7.0% during follow-up (hazard ratio, 0.56; 95% confidence interval, 0.33–0.89; P = 0.015). The cumulative development rate of malignancy other than HCC was 2.4% at 5 years, 5.1% at 10 years, and 9.8% at 15 years. Malignancies other than HCC occurred significantly when patients were of advanced age of ≤50 years, smoking index (package per day × year) was ≥ 20, and T2DM was present. T2DM caused a 1.70-fold enhancement in the development of malignancies other than HCC. Conclusion: T2DM causes an approximately 1.7-fold enhancement in the development of HCC and malignancies other than HCC in HCV-positive patients treated with IFN. In T2DM patients, maintaining a mean HbA1c level of <7.0% reduces the development of HCC. (Hepatology 2013)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943
The Natural History of Community-Acquired Hepatitis C in the United States
Alter, M. J., Margolis, H. S., Krawczynski, K., Judson, F. N., Mares, A., Alexander, W. J., Hu, P. Y., Miller, J. K., Gerber, M. A., Sampliner, R. E., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272702 · Cited by 1,592
Diabetes Mellitus and Risk of Colorectal Cancer: A Meta-Analysis
Larsson, S. C., Orsini, N., & Wolk, A. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji375 · Cited by 1,038
Cited by
EASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
Omata, M., Cheng, A.-L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K.-H., Chawla, Y. K., Shiina, S., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9799-9 · Cited by 2,171
EASL recommendations on treatment of hepatitis C: Final update of the series☆
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.018 · Cited by 1,252
EASL Recommendations on Treatment of Hepatitis C 2015
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.03.025 · Cited by 1,156
EASL Recommendations on Treatment of Hepatitis C 2016
(2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.09.001 · Cited by 985
Metadata
- Authors
- Arase, Y., Kobayashi, M., Suzuki, F., Suzuki, Y., Kawamura, Y., Akuta, N., Kobayashi, M., Sezaki, H., Saito, S., Hosaka, T., Ikeda, K., Kumada, H., & Kobayashi, T.
- Venue
- Hepatology
- Published
- 2013-03
- Volume
- 57
- Issue
- 3
- Pages
- 964-973
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1966804887
- Cited by
- 191
- References
- 4
- FWCI
- 9.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. https://app.cochat.ai/papers/10.1002/hep.26087
- The paper
- Arase, Y., Kobayashi, M., Suzuki, F., Suzuki, Y., Kawamura, Y., Akuta, N., Kobayashi, M., Sezaki, H., Saito, S., Hosaka, T., Ikeda, K., Kumada, H., & Kobayashi, T. (2013). Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology. https://doi.org/10.1002/hep.26087
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.